Key result
Astragalus polysaccharide improves survival and reduces cardiac edema in a zebrafish model of DCM.
Why the study?
Dilated cardiomyopathy has poor prognosis and genetic causes like tnnt2 mutations, but few specific drugs are available to treat mutation-induced disease.
Does Astragalus polysaccharide improve survival and cardiac function in a tnnt2a mutant zebrafish model of dilated cardiomyopathy?
Population
tnnt2a-mutant zebrafish model of dilated cardiomyopathy
Comparison
APS-treated mutant zebrafish vs untreated mutant zebrafish DCM model
Design
Preclinical animal model study
Authors
Loading...
Hypothesis-generating for Astragalus polysaccharide in dilated cardiomyopathy; should not yet inform clinical practice.
Does Astragalus polysaccharide improve survival and cardiac function in a tnnt2a mutant zebrafish model of dilated cardiomyopathy?
p-value: p=<0.01
Astragalus polysaccharide improves survival and attenuates myocardial injury in a zebrafish model of dilated cardiomyopathy by inhibiting apoptosis.
Zhou et al. (2025) studied Dilated cardiomyopathy. Astragalus polysaccharide (APS) vs. Untreated tnnt2a-/- mutant zebrafish was evaluated on Survival rate and cardiac function (heart rate, SV-BA distance) (p=<0.01). Astragalus polysaccharide significantly improved survival rate, increased heart rate, and reduced cardiac tissue edema in a tnnt2a mutant zebrafish model of dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: